2010
DOI: 10.1007/s00044-010-9516-x
|View full text |Cite
|
Sign up to set email alerts
|

3D-QSAR study of multi-target-directed AchE inhibitors based on autodocking

Abstract: We do some research about multi-targetdirected AChE inhibitors of Tacrine-Nimodipine dihydropyridine. 3D-QSAR models have been built using CoMFA and CoMSIA methods, based on compounds which are very selective and potent AChEIs and show an excellent neuroprotective profile and a moderate Ca 2? channel blockade effect. These studies indicated that the QSAR models were statistically significant and high predictable (receptor-based research CoMFA model, q 2 = 0.686, r 2 = 0.948; CoMSIA model, q 2 = 0.756, r 2 = 0.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2012
2012
2021
2021

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(3 citation statements)
references
References 18 publications
0
3
0
Order By: Relevance
“…In another work published in 2010 [42], Chen et al have studied multi-target-directed AChEIs of Tacrine-Nimodipine dihydropyridines. They establish 3D-QSAR models using CoMFA and Comparative Molecular Similarity Index Analysis (CoMSIA) methods.…”
Section: Tacrine Analoguesmentioning
confidence: 99%
“…In another work published in 2010 [42], Chen et al have studied multi-target-directed AChEIs of Tacrine-Nimodipine dihydropyridines. They establish 3D-QSAR models using CoMFA and Comparative Molecular Similarity Index Analysis (CoMSIA) methods.…”
Section: Tacrine Analoguesmentioning
confidence: 99%
“…In a recent work of 2012, Chen et al [ 26 ] have studied multi-target-directed AChEIs of Tacrine-Nimodipine dihydropyridines. They establish 3D-QSAR models using CoMFA and Comparative Molecular Similarity Index Analysis (CoMSIA) methods.…”
Section: Introductionmentioning
confidence: 99%
“…AR expression is observed in primary prostate cancer and can be detected throughout progression in both hormone-sensitive and hormone refractory cancers[ 5 ]. It is obvious that either androgen ablation and/or application of AR antagonists lead to a reduction of tumor volume and an improvement in symptoms in most of the prostate cancer patients[ 3 6 7 8 9 10 11 12 ].…”
mentioning
confidence: 99%